Alterity says it will start a Phase 2 clinical trial of ATH434 by the end of the year

[Rhyothemis]

alteritytherapeutics.com/in...

“The publication of data [mouse study] demonstrating that ATH434 preserves neurons while reducing α‑synuclein in areas of pathology is exactly what we were hoping to see as we advance to clinical trials in MSA,” said Alterity Chief Executive Officer David Stamler, M.D.,. “By targeting α‑synuclein and excess brain iron in MSA, we believe that ATH434 can treat the underlying cause of this devastating disease which has no approved therapy. We remain on track to initiate our Phase 2 clinical trial of ATH434 in patients with MSA by the end of the calendar year.”

[Kaye31]

How would you get onto a trial like this?

[Rhyothemis in reply to Kaye31]

I checked ClinicalTrials.gov and there is nothing for Alterity or ATH434 - which is interesting since they say they have completed Phase I - but no record of the Phase I in the database.

You could enquire directly:

alteritytherapeutics.com/co...

Hopefully they are legit.

[Helenhooter]

Sounds promising 🤞

[Rhyothemis in reply to Helenhooter]

I am hopeful - especially since it targets iron. I think iron homeostatis is important in a lot of conditions.

However, I am curious as to why there are no records in ClinicalTrials.gov.

[Droflet]

Really good news that this compound is showing such promise!

Here is a bit more info about how Alterity is going about designing and setting up the Phase 2 clinical trial: alteritytherapeutics.com/in...

The Recent paper in the journal Movement Disorders is here: movementdisorders.onlinelib... You'll note that the team doing the research is the one in Austria involving Gregor Wenning and Nadia Stephanova who have been pioneers of MSA research over many years and are good friends of the MSA Trust.

I think this is a really hopeful development for an eventual effective treatment of MSA. As with all research into MSA and like conditions, it will, unfortunately, still be years before the treatment is in the clinic even if the progress with the trials is good.

John

[Rhyothemis in reply to Droflet]

This is intriguing:

"The EMA has given its support to Alterity’s intention to enroll early-stage MSA patients and to utilize biomarkers to accurately diagnose these patients prior to enrolment."

So does that mean they have a way of accurately diagnosing MSA with biomarkers?!

[Rhyothemis]

Phase 2 for ATH434 has been authorized in New Zealand:alteritytherapeutics.com/in...